Impact of a value-based formulary on medication utilization, health services utilization, and expenditures

Medical Care

Volumn 55, Issue 2, 2017, Pages 191-198

  Yeung, Kai ^a   Basu, Anirban ^a   Hansen, Ryan N ^a   Watkins, John B ^a,b   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Premera Blue Cross   (United States)

Author keywords

Health insurance; Pharmaceutical policy; Pharmacoeconomics; Pharmacy benefits; Program evaluation

Indexed keywords

ADULT; AMBULATORY CARE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG MARKETING; EMERGENCY WARD; FEMALE; GROWTH; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; VALUE-BASED INSURANCE DESIGN; ADOLESCENT; CHILD; COST; DRUG UTILIZATION; ECONOMICS; FEE; FINANCIAL MANAGEMENT; HEALTH INSURANCE; HEALTH SERVICE; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PUBLICATION; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

PRESCRIPTION DRUG;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST SHARING; DRUG UTILIZATION; FEES, PHARMACEUTICAL; FINANCING, PERSONAL; FORMULARIES AS TOPIC; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INFANT; INFANT, NEWBORN; INSURANCE, PHARMACEUTICAL SERVICES; MIDDLE AGED; PRESCRIPTION DRUGS; YOUNG ADULT;

EID: 84984678136     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000630     Document Type: Article

References (43)

1. Kaiser Family Foundation and Health Research and Educational Trust. The uninsured: a primer-key facts about health insurance on the eve of coverage expansions. 2013. Available at: http://kff.org/report-section/the-uninsured-a-primer-2013-introduction/. Accessed April 22, 2014.
2. Kaiser Family Foundation and Health Research and Educational Trust. 2014 Employer Health Benefits Survey. Menlo Park, CA: KFF; 2014. Available at: http://files.kff.org/attachment/2014-employer-health-bene fits-survey-full-report. Accessed April 5, 2015.
3. Martin AB, Hartman M, Benson J, et al. National Health Expenditure accounts T. National Health spending in 2014: faster growth driven by coverage expansion and prescription drug spending. Health Aff. 2016; 35: 150-160.
4. Fendrick AM, Smith DG, Chernew ME, et al. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001; 7: 861-867.
5. Fendrick AM, Chernew ME. Value-based insurance design: a "clinically sensitive" approach to preserve quality of care and contain costs. Am J Manag Care. 2006; 12: 18-20.
6. Lee JL, Maciejewski M, Raju S, et al. Value-based insurance design: quality improvement but no cost savings. Health Aff. 2013; 32: 1251-1257.
7. Kim YA, Loucks A, Yokoyama G, et al. Evaluation of value-based insurance design with a large retail employer. Am J Manag Care. 2011; 17: 682-690.
8. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, valuebased insurance design cut copayments and increased drug adherence. Health Aff. 2010; 29: 1995-2001.
9. Maciejewski ML, Farley JF, Parker J, et al. Copayment reductions generate greater medication adherence in targeted patients. Health Aff. 2010; 29: 2002-2008.
10. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011; 30: 109-117.
11. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff. 2008; 27: 103-112.
12. Zeng F, An JJ, Scully R, et al. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010; 13: 846-852.
13. Choudhry NK, Fischer MA, Avorn JL, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012; 60: 1817-1824.
14. Gibson TB, Mahoney J, Ranghell K, et al. Value-based insurance plus disease management increased medication use and produced savings. Health Aff. 2011; 30: 100-108.
15. Chernew ME, Juster IA, Shah M, et al. Evidence that value-based insurance can be effective. Health Aff. 2010; 29: 530-536.
16. Kelly E, Turner C, Frech-Tamas F, et al. Value-based benefit design and healthcare utilization in asthma, hypertension. Am J Manage Care. 2009; 1: 217-221.
17. Maciejewski ML, Wansink D, Lindquist JH, et al. Value-based insurance design program in North Carolina increased medication adherence but was not cost neutral. Health Aff. 2014; 33: 300-308.
18. Melnick SJ, Motheral BR. Is value-based value wasted? Examining value-based insurance designs through the lens of cost-effectiveness. JMCP. 2010; 16: 130-133.
19. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011; 365: 2088-2097.
20. Fendrick AM, Smith DG, Chernew ME. Applying value-based insurance design to low-value health services. Health Aff. 2010; 29: 2017-2021.
21. Davidoff A, Lopert R, Stuart B, et al. Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes. Value Health. 2012; 15: 404-411.
22. Sullivan SD, Yeung K, Vogeler C, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015; 21: 269-275.
23. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003; 6: 9-17.
24. Baicker K, Mullainathan S, Schwartzstein J. Behavioral hazard in health insurance. Natl Bur Econ Res Bull Aging Health. 2013; 1: 2-3.
25. Basu A, Jena AB, Philipson TJ. The impact of comparative effectiveness research on health and health care spending. J Health Econ. 2011; 30: 695-706.
26. Milliman Inc. Health Cost Guidelines: Medical Rating Model. 2014.
27. Milliman Inc. Cost Relativity Analysis Model. 2014.
28. McDevitt R. Actuarial Value: A Method for Comparing Health Plan Benefits. California Healthcare Foundation; 2008.
29. U.S. Census Bureau. 2009-2013 American Community Survey 5-Year Estimates. 2015.
30. U.S. Census Bureau. 2010 U.S. Census Summary File 1. 2015.
31. Agency for Healthcare Research and Quality. National Healthcare Quality and Disparities Report and 5th Anniversary Update on the National Quality Strategy. Rockville, MD; 2016.
32. Briesacher B, Limcangco R, Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. Health Care Financ Rev. 2003; 25: 63-76.
33. Cook BL, Manning WG. Measuring racial/ethnic disparities across the distribution of health care expenditures. Health Serv Res. 2009; 44(pt 1): 1603-1621.
34. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27: 299-309.
35. Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013; 13(suppl): S38-S44.
36. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd ed. NY, New York: Wiley; 2000.
37. Pregibon D. Goodness of link tests for generalized linear models. Appl Stat. 1980; 29: 15-24.
38. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000; 56: 645-646.
39. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43: 1130-1139.
40. Center for Medicare and Medicaid Innovation. Announcement of Medicare Advantage Value-Based Insurance Design Model Test. Department of Health and Human Services; 2015.
41. Ubel PA. Value Promotion in health care: the importance of symmetry. JAMA. 2016; 315: 133-134.
42. Brook RH, Ware JE Jr, Rogers WH, et al. Does free care improve adults' health? Results from a randomized controlled trial. N Engl J Med. 1983; 309: 1426-1434.
43. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006; 354: 2349-2359.